Blog
RSS FeedPosted by Michael Wonder on 24 Jan 2020
After years of campaigning, PHARMAC agrees to fund 'wonder drug' to treat kids with cystic fibrosis
24 January 2020 - PHARMAC has reached a provisional agreement with medicine supplier Vertex to fund the long-campaigned for drug Kalydeco ...
Posted by Michael Wonder on 24 Jan 2020
FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer
23 January 2020 - Today, the U.S. Food and Drug Administration granted accelerated approval to Tazverik (tazemetostat) for the treatment of ...
Posted by Michael Wonder on 24 Jan 2020
PHARMAC seeking views on new cystic fibrosis medicine
24 January 2020 - PHARMAC has reached a provisional agreement with medicine supplier Vertex to fund ivacaftor (marketed as Kalydeco) ...
Posted by Michael Wonder on 24 Jan 2020
ICER releases draft evidence report on therapies for sickle cell disease
23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures ...
Posted by Michael Wonder on 24 Jan 2020
Ready for rescue – new nasally administered glucagon for severe hypoglycaemia available in Canada
23 January 2020 - Eli Lilly Canada introduces Baqsimi, another Canadian innovation to help manage diabetes complications. ...
Posted by Michael Wonder on 24 Jan 2020
HLS Therapeutics files new drug submission for Perseris in Canada
23 January 2020 - If approved by Health Canada, Perseris would become the first once-monthly risperidone long-acting injectable used in the ...
Posted by Michael Wonder on 24 Jan 2020
Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with advanced renal cell carcinoma
23 January 2020 - Approval based on results of KEYNOTE-426, Where Keytruda in combination with axitinib reduced the risk of death ...
Posted by Michael Wonder on 23 Jan 2020
Health Technology Assessment around the world: broadening the understanding of cross-country differences
22 January 2020 - Value in Health, the official journal of ISPOR—the professional society for health economics and outcomes research, ...
Posted by Michael Wonder on 23 Jan 2020
Woman denied cancer drug on NHS which could extend her life because of where she lives
22 January 2020 - Ann, 64, can't get the drug she needs to survive because it's not available on the NHS ...
Posted by Michael Wonder on 23 Jan 2020
PHARMAC protest ride from Dunedin ends with conflict in Parliament
22 January 2020 - A couple’s tandem cycle ride from Dunedin to Wellington, to call for increased PHARMAC funding, has ...
Posted by Michael Wonder on 23 Jan 2020
The intricacies of rising drug prices in the US
23 January 2020 - Following 250 US drug price increases in 2020 already, this article explores why costs are rising, what ...
Posted by Michael Wonder on 23 Jan 2020
Want to know how contentious drug pricing is in Washington? Check the receipts.
23 January 2020 - Pfizer, Johnson & Johnson, Merck, and the 31 other major drug makers that belong to the ...
Posted by Michael Wonder on 23 Jan 2020
Baudax Bio announces PDUFA date for intravenous meloxicam
22 January 2020 - Baudax Bio today announced that the U.S. FDA has set a PDUFA goal date of 20 ...
Posted by Michael Wonder on 23 Jan 2020
Sick of high drug prices, insurers join hospitals to make their own generic medications
23 January 2020 - Everyone complains about high drug prices. But hospitals — and now insurers — are trying to ...
Posted by Michael Wonder on 23 Jan 2020
Update of the frequently asked questions for the PBS Botulinum Toxin Program
23 January 2020 - A revised version of the frequently asked questions for the PBS Botulinum Toxin Program is now available. ...